This site is intended for health professionals only!

Published on 16 July 2007

Share this story:

No post-cardioversion gain from ARB

teaser

Treatment with an angiotensin II receptor type I blocker (ARB) before and after electrical cardioversion does not reduce recurrence of atrial fibrillation (AF), results of a randomised, placebo-controlled trial indicate.

Patients with persistent AF are usually treated using a “rhythm-control” strategy with electrical cardioversion used to restore sinus rhythm, explained Dr Arnljot Tveit of Asker and B



Most read




Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: